文献速递脊柱关节炎

axSpA患者主观性TNFi应答丧失与MRI骨髓水肿复发相关且长效制剂更明显

Subjective loss of clinical response to TNFi in axSpA relates to recurrence of MRI bone marrow oedema particularly with long-acting agents.
PubMed 文献 · Rheumatology (Oxford) · 2022-01-01

该概念验证研究纳入38例已稳定使用依那西普、阿达木单抗或英夫利西单抗的axSpA患者,在下次给药前、给药后4天及症状复发时行MRI和临床评估。结果显示给药后临床应答改善且MRI-BMO数值减少,症状复发时英夫利西单抗组新发BMO病变较多,但样本量不足以行统计学检验。

要点

  • axSpA患者下次TNFi给药前可出现主观应答丧失,与MRI骨髓水肿复发相关。
  • 给药后4天临床应答改善且MRI-BMO数值减少,提示短期波动。
  • 长效制剂组症状复发时新发BMO病变相对较多,但样本量小未行统计检验。

核心结论

  • MRI-BMO短期波动在长效TNFi中更常见,并与下次给药前主观临床应答丧失相对应。
  • 需更大样本研究确认该现象的致病意义。

研究设计与样本

  • 概念验证研究,纳入38例已稳定使用依那西普、阿达木单抗或英夫利西单抗的axSpA患者。
  • 在计划给药前(v1)、给药后4天(v2)及患者报告症状复发时(v3)采集MRI和临床数据。
  • 采用3T MRI评估脊柱/骶髂关节,使用半定量Leeds MRI评分系统评分。

主要发现

  • 共完成113次临床评估和MRI;阿达木单抗16例、依那西普12例、英夫利西单抗10例;平均年龄42.1岁±24.4(2SD,n=38),男性71.1%(27/38),HLA-B27阳性69.7%(23/33)。
  • v1时所有患者疾病活动度高[ASDAS-CRP=3(2.7-3.7)],57.9%存在MRI-BMO(BMO数量:依那西普26、阿达木单抗59、英夫利西单抗28)。
  • v2临床应答改善[ASDAS-CRP -0.41(-0.81至-0.30),P=0.018;BASDAI -0.58(-2.2至0.52),P=0.024]。
  • v1至v2仅间隔4天,MRI-BMO病变呈数值下降(依那西普-6、阿达木单抗-10、英夫利西单抗-3)。
  • v3时依那西普和阿达木单抗组新发BMO病变相对少于英夫利西单抗(依那西普-1、阿达木单抗+3、英夫利西单抗+8),但数量太小无法行统计学显著性检验。

关键数值与推荐

  • v1时高疾病活动度定义为ASDAS-CRP=3(2.7-3.7)。
  • v2时ASDAS-CRP较v1变化-0.41(-0.81至-0.30),P=0.018。
  • v2时BASDAI较v1变化-0.58(-2.2至0.52),P=0.024。
  • v1时57.9%患者存在MRI-BMO。

临床怎么用

  • 对axSpA患者下次TNFi给药前出现主观应答丧失时,可考虑MRI评估骨髓水肿复发。
  • 长效TNFi制剂可能与更明显的MRI-BMO短期波动相关,临床需关注给药间期症状变化。
  • 目前证据尚不足以据此调整TNFi选择或给药方案,需更大样本验证。

局限性

  • 概念验证研究,样本量小(38例),v3时新发BMO病变数量太少无法行统计学显著性检验。
  • 原文未报告盲法、随机化或对照设置等细节。
  • 原文未报告随访时长及研究注册信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Subjective loss of response immediately prior to routine TNFi therapy can occur in axial spondyloarthritis (axSpA). We investigated clinical outcomes in patients taking the first three licenced TNFis and correlated this with recurrence of MRI bone marrow oedema (MRI-BMO). METHODS: Proof-of-concept study including axSpA patients established on etanercept (ETA), adalimumab (ADA) or infliximab (IFX) reporting symptom deterioration prior to next dose. MRI/clinical data were collected prior to scheduled dose (v1), 4 days post-dose (v2) and at the time of patient-reported symptom return (v3). MRI spine/sacroiliac joints utilizing 3 T were scored using the semi-quantitative Leeds MRI scoring system. RESULTS: A total of 113 clinical assessments and MRIs were performed in 38 participants (ADA = 16, ETA = 12, IFX = 10), mean age 42.1 years ± 24.4(2SD, n = 38), 71.1% male (n = 27/38), 69.7% HLA-B27 positive (n = 23/33). At v1, all patients had high disease activity [ASDAS-CRP = 3 (2.7-3.7)] and 57.9% had MRI-BMO (number of MRI-BMO: ETA = 26, ADA = 59, IFX = 28). Improved clinical responses were seen at v2 [ASDAS-CRP -0.41(-0.81 - 0.30), P =0.018; BASDAI -0.58(-2.2 - 0.52), P =0.024]. Despite just a 4-day interval between v1 and v2, a numerical reduction in MRI-BMO lesions between v1/v2 was observed (ETA = -6, ADA = -10, IFX = -3). By v3, comparatively fewer new BMO lesions were detected in the ETA and ADA groups compared with IFX (ETA = -1, ADA = +3, IFX = +8), although the numbers were too small to enable testing for statistical significance. CONCLUSIONS: Short-lived fluctuations in MRI-BMO were commoner with longer-acting agents and corresponded with subjective loss of clinical response before next scheduled TNFi dose. Larger studies are needed to confirm the possible pathogenic implications of this phenomenon.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Harrison SR, Ansell R, Mathieson HR, et al. Subjective loss of clinical response to TNFi in axSpA relates to recurrence of MRI bone marrow oedema particularly with long-acting agents. Rheumatology (Oxford). 2022. PMID: 34273162. doi:10.1093/rheumatology/keab571

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。